1; Mandac Smoljanovi, Inga 2. Gynecol. Management of infusion reactions to systemic anticancer therapy: ESMO doi: 10.1002/pbc.25697, Siegel, R. L., Miller, K. D., and Jemal, A. Cumulative incidence of carboplatin-related hypersensitivity reactions according to the carboplatin administration cycle number (A) and carboplatin dose (B). Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P. 19, 460465. Ovarian cancer is the leading cause of death from gynecological malignancies (Chiang et al., 2013), with a 5-year survival rate of 46% in the United States (92% when localized, 73% with regional metastases, and 28% with distant metastases) (Siegel et al., 2016). Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies. Wang, H. B., Shen, K., Yang, J. X., Huang, H. F., Li, Y., Wu, M., et al. doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Open. B., Phillips, P. C., Kang, T. I., et al. Successful carboplatin desensitization in patients with proven carboplatin allergy. Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan Oncology 61, 129133. ESMO Virtual Congress 2020 | OncologyPRO Za. Request PDF | On Jul 13, 2017, Susana Rosell Kernen published Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines | Find, read and cite all the . Analysis included treatment cycle, causative drug, severity of reaction as per CTCAE v4 . Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Lancet Oncol. With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). For more detailed information on the cookies we use, please check our Privacy Policy. Epub 2017 Feb 24. The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics. Skin Testing and Basophil Activation Testing Is Useful for Assessing Immediate Reactions to Polyethylene Glycol-Containing Vaccines. government site. J. Gynecol. official website and that any information you provide is encrypted 24, 342351. Parmar et al. Tamiya, M., Kuhara, H., Hirashima, T., Kondo, Y., Santo, M., Morishita, N., et al. (2009). (2013). Metrics. Symptoms and signs of hypersensitivity reactions amendable to desensitization. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. Reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications are especially important for patients at high risk of carboplatin hypersensitivity to detect the hypersensitivity early and avoid severe hypersensitivity without compromising the efficacy of the antineoplastic regimen. In our study, 36% of the patients with carboplatin-related hypersensitivity reactions had a history of drug allergies. Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. Disclaimer. Integrating science into oncology for a better patient outcome, ESMO Designated Centres Community Session, Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the. Int. Death from anaphylaxis to cisplatin: a case report. (2013). Hypersensitivity to antineoplastic agents. (2010) described the use of cisplatin as an alternative to carboplatin. doi: 10.1200/JOP.18.00761. J. Clin. Tachycardia and dyspnea persisted despite treatment with hydration, antihistamines, corticosteroids, and an oxygen mask. doi: 10.1007/s00520-011-1123-y, Gomez, R., Harter, P., Lck, H. J., Traut, A., Kommoss, S., Kandel, M., et al. Adnan A, Acharya S, Alenazy LA, de Las Vecillas L, Giavina Bianchi P, Picard M, Calbache-Gil L, Romero-Pinedo S, Abad A-Molina AC, Kerr W, Pedicone C, Nagai J, Hollers E, Dwyer D, Castells M. J Immunol. J. Clin. Read guidelines by topic Latest Guidelines News Unauthorized use of these marks is strictly prohibited. doi: 10.1111/IGC.0b013e3181a1bf2e, Ledermann, J. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? Carboplatin hypersensitivity: evaluation and successful desensitization protocol. Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Cancer statistics, 2016. Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Management of infusion reactions to systemic anticancer therapy: ESMO 2023 Feb 15;24(4):3886. doi: 10.3390/ijms24043886. Monitor. A cumulative carboplatin dose >4,000 mg significantly positively correlated with carboplatin hypersensitivity. For more detailed information on the cookies we use, please check our Privacy Policy. Oncol. These risk factors can help identify patients at greater risk of developing hypersensitivity. PDF Management of Immune-related Adverse Events in Patients Treated - Asco WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . Zhonghua. 107, 163165. Accessibility ESMO is a Swiss-registered not-for-profit organisation. Therefore, the preferred regimen for platinum-sensitive recurrent ovarian cancer is carboplatin combined with paclitaxel, liposomal doxorubicin, or gemcitabine. Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. E. Restuccia: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: Genentech, Inc; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Loibl: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: AbbVie; Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Advisory Board: Celgene; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Advisory Board: PriME/ Medscape; Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Research Grant: Teva; Financial Interests, Personal, Research Grant: Vifor; Financial Interests, Institutional, Research Grant: Daiichi-Sankyo; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: Samsung; Financial Interests, Institutional, Advisory Board: Eirgenix; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Puma; Financial Interests, Personal, Research Grant: Immunomedics; Non-Financial Interests, Personal, Other, Patent EP14153692 .0 pending: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Institutional, Advisory Board: MSD. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). 144, 7782. This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). Gynecol. Bookshelf Rosell S, Blasco I, Garca Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee. 329 (152 CPI-treated v 177 CPI-nave, including 60 tx-nave) pts with RET fusion+ NSCLC were analyzed. Hypersensitivity reactions are generally unexpected, regulated by the immune system, and allergic in nature. (2005). Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2020 Ann Oncol (2020)Authors:M.E. Acquisition of data: Y-HT, S-PL, Y-CC, Y-LC. Drug allergy is a rising problem in the twenty-first century which affects all populations and races, children, and adults, and for which the recognition, diagnosis, management, and treatment is still not well standardized. Infusion reactions to systemic chemotherapy - UpToDate ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Bookshelf 53, 121122. The results of the trial could answer whether carboplatin hypersensitivity patients have similar chemo-responses in non-platinum regimens without compromising the efficacy of the antineoplastic regimens of these patients. The rate of hypersensitivity was significantly higher among patients with advanced stage disease (IIIIV) compared to patients with early stage disease (III) (P < 0.001, Kruskal-Wallis test), and among patients with serous or mixed histological type compared to patients with other histological types (P = 0.003, Kruskal-Wallis test). Cancer. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Necessary cookies enable core functionality. Monitor. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. del Carmen Sancho M, Breslow R, Sloane D, Castells M. Chem Immunol Allergy. An official website of the United States government. The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. PDF Hypersensitivity & Infusion Reaction Management - Stephenson Cancer Center The https:// ensures that you are connecting to the Such reactions were scored according to the Common Terminology Criteria for Adverse Events version 4.03, with severity assessed as mild (grades 1 and 2) or severe (grades 3 and 4).
Rodeo Stampede Best Sidekick,
Elemental Grind Game Script,
David Milliken Diesel Performance Texas,
Justice Of Peace Casuarina,
Articles E